Lawrence A. Leiter




Please note: Dr. Leiter is not taking any summer students.

Dr. Lawrence A. Leiter is Director of the Lipid Clinic, Associate Director of the Clinical Nutrition and Risk Factor Modification Centre and an Associate Scientist in the Li Ka Shing Knowledge Institute of St. Michael’s Hospital in Toronto.  From 2000-2010, he was Head of the Division of Endocrinology and Metabolism. He is a Professor in the Departments of Medicine and Nutritional Sciences at the University of Toronto.

Dr. Leiter has several research interests including clinical trials on the prevention of atherosclerosis, especially in diabetes, and the dietary and pharmacologic treatment of diabetes mellitus, hyperlipidemia, hypertension, and obesity. He has over 750 publications in peer-reviewed journals. He was an investigator in many of the landmark diabetes trials including the Diabetes Control and Complications Trial (DCCT), Action to Control Cardiovascular Risk in Diabetes (ACCORD), and Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) and is on the Steering Committees of many ongoing outcome trials in both the diabetes and lipid areas. In 2018, 2019, and 2020 he was a Clarivate Analytics Top 1% Highly Cited Researcher

Dr. Leiter is a past President of the Canadian Society of Endocrinology & Metabolism (CSEM) and a past Chair of the Clinical and Scientific Section of the Canadian Diabetes Association (CDA). He has been involved in many national and international committees and consensus conferences including those of the International Diabetes Federation, CDA, Canadian Hypertension Education Program (CHEP), Canadian Cardiovascular Society (Dyslipidemia), and Obesity Canada.

For his work, he has received a number of awards including the CDA Frederick G. Banting Award and the American Diabetes Association Charles H Best Award (awarded to DCCT investigators), both for Distinguished Service. In 2016, Dr. Leiter received the Canadian Diabetes Association Long Term Achievement Award for Research and the Canadian Society of Endocrinology’s Robert Volpe Distinguished Service Award. He was also the inaugural winner of the St. Michael’s Hospital Complete Physician Award in 2009.  In 2019 was elected as a Fellow of the Canadian Academy of Health Sciences

Recent Publications

  1. Langer, A, Mancini, GBJ, Tan, M, Goodman, SG, Ahooja, V, Grégoire, J et al.. Treatment Inertia in Patients With Familial Hypercholesterolemia. J Am Heart Assoc. 2021;10 (14):e020126. doi: 10.1161/JAHA.120.020126. PubMed PMID:34238023 .
  2. Mosenzon, O, Wiviott, SD, Heerspink, HJL, Dwyer, JP, Cahn, A, Goodrich, EL et al.. The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58. Diabetes Care. 2021; :. doi: 10.2337/dc21-0076. PubMed PMID:34233928 .
  3. Sharma, A, Aziz, H, Verma, S, Abramson, BL, Choi, R, Chua, GL et al.. Permission to prescribe: do cardiologists need permission to prescribe diabetes medications that afford cardiovascular benefit?. Curr Opin Cardiol. 2021; :. doi: 10.1097/HCO.0000000000000892. PubMed PMID:34173772 .
  4. Bajaj, HS, Gerstein, HC, Rao-Melacini, P, Basile, J, Colhoun, H, Conget, I et al.. Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial. Lancet Diabetes Endocrinol. 2021;9 (8):484-490. doi: 10.1016/S2213-8587(21)00115-7. PubMed PMID:34153269 .
  5. Szarek, M, Bhatt, DL, Steg, PG, Cannon, CP, Leiter, LA, McGuire, DK et al.. Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure : A Randomized Trial. Ann Intern Med. 2021; :. doi: 10.7326/M21-0651. PubMed PMID:34152828 .
  6. Verma, S, Leiter, LA, Zinman, B, Sharma, A, Mattheus, M, Fitchett, D et al.. Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA-REG OUTCOME trial. ESC Heart Fail. 2021;8 (4):2603-2607. doi: 10.1002/ehf2.13374. PubMed PMID:34132492 .
  7. Ayoub-Charette, S, Chiavaroli, L, Liu, Q, Khan, TA, Zurbau, A, Au-Yeung, F et al.. Different Food Sources of Fructose-Containing Sugars and Fasting Blood Uric Acid Levels: A Systematic Review and Meta-Analysis of Controlled Feeding Trials. J Nutr. 2021; :. doi: 10.1093/jn/nxab144. PubMed PMID:34087940 .
  8. Mann, JFE, Buse, JB, Idorn, T, Leiter, LA, Pratley, RE, Rasmussen, S et al.. Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis. Diabetes Obes Metab. 2021; :. doi: 10.1111/dom.14443. PubMed PMID:34009708 .
  9. Leiter, LA, Bhatt, DL, McGuire, DK, Teoh, H, Fox, K, Simon, T et al.. Diabetes-Related Factors and the Effects of Ticagrelor Plus Aspirin in the THEMIS and THEMIS-PCI Trials. J Am Coll Cardiol. 2021;77 (19):2366-2377. doi: 10.1016/j.jacc.2021.03.298. PubMed PMID:33985681 .
  10. Bosch, J, Lonn, EM, Dagenais, GR, Gao, P, Lopez-Jaramillo, P, Zhu, J et al.. Antihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 Trial. Stroke. 2021;52 (8):2494-2501. doi: 10.1161/STROKEAHA.120.030790. PubMed PMID:33985364 .
Search PubMed

Affiliations & Other Activities

  • Director, Lipid Clinic, St. Michael’s Hospital
  • Associate Director, Clinical Nutrition and Risk Factor Modification Centre, St. Michael’s Hospital
  • Professor, Departments of Medicine and Nutritional Sciences, University of Toronto